Permanent prostate seed implant brachytherapy: report of the American Association of Physicists in Medicine Task Group No. 64.

There is now considerable evidence to suggest that technical innovations, 3D image-based planning, template guidance, computerized dosimetry analysis and improved quality assurance practice have converged in synergy in modern prostate brachytherapy, which promise to lead to increased tumor control and decreased toxicity. A substantial part of the medical physicist's contribution to this multi-disciplinary modality has a direct impact on the factors that may singly or jointly determine the treatment outcome. It is therefore of paramount importance for the medical physics community to establish a uniform standard of practice for prostate brachytherapy physics, so that the therapeutic potential of the modality can be maximally and consistently realized in the wider healthcare community. A recent survey in the U.S. for prostate brachytherapy revealed alarming variance in the pattern of practice in physics and dosimetry, particularly in regard to dose calculation, seed assay and time/method of postimplant imaging. Because of the large number of start-up programs at this time, it is essential that the roles and responsibilities of the medical physicist be clearly defined, consistent with the pivotal nature of the clinical physics component in assuring the ultimate success of prostate brachytherapy. It was against this background that the Radiation Therapy Committee of the American Association of Physicists in Medicine formed Task Group No. 64, which was charged (1) to review the current techniques in prostate seed implant brachytherapy, (2) to summarize the present knowledge in treatment planning, dose specification and reporting, (3) to recommend practical guidelines for the clinical medical physicist, and (4) to identify issues for future investigation.

[1]  Ravinder Nath,et al.  Dosimetry of interstitial brachytherapy sources: Recommendations of the AAPM Radiation Therapy Committee Task Group No. 43 , 1995 .

[2]  P. Okunieff,et al.  Intraoperative optimized inverse planning for prostate brachytherapy: early experience. , 1999, International journal of radiation oncology, biology, physics.

[3]  J. Williamson,et al.  Guidance to users of Nycomed Amersham and North American Scientific, Inc., I-125 interstitial sources: dosimetry and calibration changes: recommendations of the American Association of Physicists in Medicine Radiation Therapy Committee Ad Hoc Subcommittee on Low-Energy Seed Dosimetry. , 1999, Medical physics.

[4]  P. Okunieff,et al.  Automated treatment planning engine for prostate seed implant brachytherapy. , 1999, International journal of radiation oncology, biology, physics.

[5]  R Nath,et al.  Correlation of medical dosimetry quality indicators to the local tumor control in patients with prostate cancer treated with iodine-125 interstitial implants. , 1998, Medical physics.

[6]  P L Carson,et al.  Real-time B-mode ultrasound quality control test procedures. Report of AAPM Ultrasound Task Group No. 1. , 1998, Medical physics.

[7]  J J Prete,et al.  Centralized multiinstitutional postimplant analysis for interstitial prostate brachytherapy. , 1998, International journal of radiation oncology, biology, physics.

[8]  G S Merrick,et al.  Quality assurance calibration of 125I rapid strand in a sterile environment. , 1998, International journal of radiation oncology, biology, physics.

[9]  R. Stock,et al.  A dose-response study for I-125 prostate implants. , 1998, International journal of radiation oncology, biology, physics.

[10]  J J Prete,et al.  Timing of computed tomography-based postimplant assessment following permanent transperineal prostate brachytherapy. , 1998, International journal of radiation oncology, biology, physics.

[11]  B. Prestidge,et al.  Clinical impact of implementing the recommendations of AAPM Task Group 43 on permanent prostate brachytherapy using 125I. American Association of Physicists in Medicine. , 1998, International journal of radiation oncology, biology, physics.

[12]  J J Prete,et al.  A survey of physics and dosimetry practice of permanent prostate brachytherapy in the United States. , 1998, International journal of radiation oncology, biology, physics.

[13]  J. Williamson,et al.  Report of the ad hoc committee of the AAPM radiation therapy committee on 125I sealed source dosimetry. , 1998, International journal of radiation oncology, biology, physics.

[14]  N. Yue,et al.  Edema associated with I-125 or Pd-103 prostate brachytherapy and its impact on post-implant dosimetry: an analysis based on serial CT acquisition. , 1998, International Journal of Radiation Oncology, Biology, Physics.

[15]  R. Stock,et al.  Acute urinary morbidity following I-125 interstitial implantation of the prostate gland. , 1998, Radiation oncology investigations.

[16]  J J Prete,et al.  Source localization following permanent transperineal prostate interstitial brachytherapy using magnetic resonance imaging. , 1997, International journal of radiation oncology, biology, physics.

[17]  J F Williamson,et al.  Code of practice for brachytherapy physics: report of the AAPM Radiation Therapy Committee Task Group No. 56. American Association of Physicists in Medicine. , 1997, Medical physics.

[18]  Y. Yu,et al.  Multiobjective decision theory for computational optimization in radiation therapy. , 1997, Medical physics.

[19]  P L Roberson,et al.  Impact of ultrasound and computed tomography prostate volume registration on evaluation of permanent prostate implants. , 1997, International journal of radiation oncology, biology, physics.

[20]  K. Wallner,et al.  CT-based dosimetry for transperineal I-125 prostate brachytherapy. , 1997, International journal of radiation oncology, biology, physics.

[21]  J. Blasko,et al.  Interstitial iodine‐125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma , 1997, Cancer.

[22]  M. Zelefsky,et al.  Long-term results of retropubic permanent 125iodine implantation of the prostate for clinically localized prostatic cancer. , 1997, The Journal of urology.

[23]  Y Chen,et al.  Treatment planning for prostate implant with loose seeds. , 1997, Medical physics.

[24]  M Dattoli,et al.  A simple method to stabilize the prostate during transperineal prostate brachytherapy. , 1997, International journal of radiation oncology, biology, physics.

[25]  B W Corn,et al.  Effect of edema on the post-implant dosimetry of an I-125 prostate implant: a case study. , 1997, International journal of radiation oncology, biology, physics.

[26]  P L Roberson,et al.  Impact of differences in ultrasound and computed tomography volumes on treatment planning of permanent prostate implants. , 1997, International journal of radiation oncology, biology, physics.

[27]  M A Moerland,et al.  Evaluation of permanent I-125 prostate implants using radiography and magnetic resonance imaging. , 1997, International journal of radiation oncology, biology, physics.

[28]  M. Moerland,et al.  A conformation number to quantify the degree of conformality in brachytherapy and external beam irradiation: application to the prostate. , 1997, International journal of radiation oncology, biology, physics.

[29]  P. Roberson,et al.  Source placement error for permanent implant of the prostate. , 1997, Medical physics.

[30]  D. Beyer,et al.  Biochemical disease-free survival following 125I prostate implantation. , 1997, International journal of radiation oncology, biology, physics.

[31]  J. Blasko,et al.  A method for implementing the American Association of Physicists in Medicine Task Group-43 dosimetry recommendations for 125I transperineal prostate seed implants on commercial treatment planning systems. , 1997, International journal of radiation oncology, biology, physics.

[32]  S. Stokes,et al.  Transperineal ultrasound-guided radioactive seed implantation for organ-confined carcinoma of the prostate. , 1997, International journal of radiation oncology, biology, physics.

[33]  J. Blasko,et al.  Posttreatment biopsy results following interstitial brachytherapy in early-stage prostate cancer. , 1997, International journal of radiation oncology, biology, physics.

[34]  Y Yu,et al.  A genetic algorithm for the optimization of prostate implants. , 1996, Medical physics.

[35]  A simple method for verifying activity of iodine-125 seeds in rigid absorbable suture. , 1996, Medical dosimetry : official journal of the American Association of Medical Dosimetrists.

[36]  J. Pouliot,et al.  Optimization of permanent 125I prostate implants using fast simulated annealing. , 1996, International journal of radiation oncology, biology, physics.

[37]  H. Hricak,et al.  Prostate volumes defined by magnetic resonance imaging and computerized tomographic scans for three-dimensional conformal radiotherapy. , 1996, International journal of radiation oncology, biology, physics.

[38]  Y. Yu A nondivergent specification of the mean treatment dose in interstitial brachytherapy. , 1996, Medical physics.

[39]  J. Pow-Sang,et al.  Improvement in dosimetry of ultrasound-guided prostate implants with the use of multiple stabilization needles. , 1996, Medical dosimetry : official journal of the American Association of Medical Dosimetrists.

[40]  R. Stock,et al.  Sexual potency following interactive ultrasound-guided brachytherapy for prostate cancer. , 1996, International journal of radiation oncology, biology, physics.

[41]  P L Roberson,et al.  Optimal placement of radioisotopes for permanent prostate implants. , 1996, Radiology.

[42]  J Roy,et al.  Tumor control and morbidity following transperineal iodine 125 implantation for stage T1/T2 prostatic carcinoma. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  F M Waterman,et al.  Limitations of the minimum peripheral dose as a parameter for dose specification in permanent 125I prostate implants. , 1996, International journal of radiation oncology, biology, physics.

[44]  C. Clifton Ling,et al.  Determining source strength and source distribution for a transperineal prostate implant , 1996 .

[45]  W. Butler,et al.  I‐125 Rapid Strand™ loading technique , 1996 .

[46]  A. D'Amico,et al.  Role of interstitial radiotherapy in the management of clinically organ-confined prostate cancer: the jury is still out. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  J. Blasko,et al.  Prostate specific antigen based disease control following ultrasound guided 125iodine implantation for stage T1/T2 prostatic carcinoma. , 1995, The Journal of urology.

[48]  R. Kline,et al.  Verification of manufacturer-supplied 125I and 103Pd air-kerma strengths. , 1995, Medical physics.

[49]  J. Roy,et al.  Dosimetry guidelines to minimize urethral and rectal morbidity following transperineal I-125 prostate brachytherapy. , 1995, International journal of radiation oncology, biology, physics.

[50]  C C Ling,et al.  The relative biological effectiveness of I-125 and Pd-103. , 1995, International journal of radiation oncology, biology, physics.

[51]  R. Stock,et al.  A modified technique allowing interactive ultrasound-guided three-dimensional transperineal prostate implantation. , 1995, International journal of radiation oncology, biology, physics.

[52]  J. Payne,et al.  Original Articles: Prostate Cancer , 1995 .

[53]  L. Anderson,et al.  Dosimetry of interstitial brachytherapy sources: Recommendations of the AAPM Radiation Therapy Committee Task Group No. 43 , 1995 .

[54]  R. Stock,et al.  Prostate brachytherapy: Improvements in prostate volume measurements and dose distribution using interactive ultrasound guided implantation and three-dimensional dosimetry , 1995 .

[55]  S Nag,et al.  Transperineal palladium 103 prostate brachytherapy: analysis of morbidity and seed migration. , 1995, Urology.

[56]  J. Payne,et al.  Detailed preliminary analysis of 125iodine implantation for localized prostate cancer using percutaneous approach. , 1995, The Journal of urology.

[57]  J. Roy,et al.  Short-term freedom from disease progression after I-125 prostate implantation. , 1994, International journal of radiation oncology, biology, physics.

[58]  Julie Dawson,et al.  Dose effects of seeds placement deviations from pre-planned positions in ultrasound guided prostate implants , 1994 .

[59]  J Roy,et al.  Fluoroscopic visualization of the prostatic urethra to guide transperineal prostate implantation. , 1994, International journal of radiation oncology, biology, physics.

[60]  J. Palta,et al.  Comprehensive QA for radiation oncology: report of AAPM Radiation Therapy Committee Task Group 40. , 1994, Medical physics.

[61]  J. Roy,et al.  Quantifying the effect of dose inhomogeneity in brachytherapy: application to permanent prostatic implant with 125I seeds. , 1994, International journal of radiation oncology, biology, physics.

[62]  J Roy,et al.  Treatment-related symptoms during the first year following transperineal 125I prostate implantation. , 1994, International journal of radiation oncology, biology, physics.

[63]  Ultrasound guided placement of transperineal prostatic afterloading catheters. , 1994, International journal of radiation oncology, biology, physics.

[64]  T. D. de Reijke,et al.  Analysis of biopsy findings and implant quality following ultrasonically-guided 125I implantation for localised prostatic carcinoma. , 1993, British journal of urology.

[65]  Blasko,et al.  Brachytherapy and Organ Preservation in the Management of Carcinoma of the Prostate. , 1993, Seminars in radiation oncology.

[66]  L L Anderson,et al.  A nomograph for permanent implants of palladium-103 seeds. , 1993, International journal of radiation oncology, biology, physics.

[67]  J. Roy,et al.  Tumor control probability for permanent implants in prostate. , 1993, Radiotherapy and Oncology.

[68]  C C Ling,et al.  A CT-based evaluation method for permanent implants: application to prostate. , 1993, International journal of radiation oncology, biology, physics.

[69]  J Roy,et al.  Short-term morbidity from CT-planned transperineal I-125 prostate implants. , 1993, International journal of radiation oncology, biology, physics.

[70]  S. Kandzari,et al.  Iodine 125 seed implants for prostatic carcinoma. Five- and ten-year follow-up. , 1993, Urology.

[71]  D. Beyer,et al.  Guided brachytherapy for treatment of confined prostate cancer. , 1992, Urology.

[72]  R. Nath,et al.  Tissue inhomogeneity correction for brachytherapy sources in a heterogeneous phantom with cylindrical symmetry. , 1992, Medical physics.

[73]  R. Nath,et al.  Interseed effects on dose for 125I brachytherapy implants. , 1992, Medical physics.

[74]  J. Payne,et al.  Improved technique for prostate seed implantation: combined ultrasound and fluoroscopic guidance , 1992 .

[75]  R Nath,et al.  Some treatment planning considerations for 103Pd and 125I permanent interstitial implants. , 1992, International journal of radiation oncology, biology, physics.

[76]  C. Ling Permanent implants using Au-198, Pd-103 and I-125: radiobiological considerations based on the linear quadratic model. , 1992, International journal of radiation oncology, biology, physics.

[77]  L. Blank,et al.  Treatment of localized prostatic carcinoma using the transrectal ultrasound guided transperineal implantation technique. , 1992, European urology.

[78]  A. van't Riet,et al.  Ultrasonically guided transperineal seed implantation of the prostate: modification of the technique and qualitative assessment of implants. , 1992, International journal of radiation oncology, biology, physics.

[79]  C. Ling,et al.  Clinical implications of I-125 dosimetry of bone and bone-soft tissue interfaces. , 1991, International journal of radiation oncology, biology, physics.

[80]  L. Brady,et al.  External beam irradiation versus 125 iodine implant in the definitive treatment of prostate carcinoma. , 1991, International journal of radiation oncology, biology, physics.

[81]  C B Begg,et al.  The effect of local control on metastatic dissemination in carcinoma of the prostate: long-term results in patients treated with 125I implantation. , 1991, International journal of radiation oncology, biology, physics.

[82]  J Roy,et al.  An improved method for computerized tomography-planned transperineal 125iodine prostate implants. , 1991, The Journal of urology.

[83]  J. Roy,et al.  CT-based optimized planning for transperineal prostate implant with customized template. , 1991, International journal of radiation oncology, biology, physics.

[84]  H. Holm,et al.  Long-term results of ultrasonically guided implantation of 125-I seeds combined with external irradiation in localized prostatic cancer. , 1991, Scandinavian journal of urology and nephrology. Supplementum.

[85]  C. Saw,et al.  Quantitative assessment of interstitial implants. , 1991, International journal of radiation oncology, biology, physics.

[86]  C. Ling,et al.  Dose distribution of 125I sources in different tissues. , 1990, Medical physics.

[87]  M. Zaider,et al.  The relative biological effectiveness of photon radiation from encapsulated iodine-125, assessed in cells of human origin: I. Normal diploid fibroblasts. , 1990, International journal of radiation oncology, biology, physics.

[88]  Lowell L. Anderson,et al.  Interstitial Brachytherapy: Physical, Biological, and Clinical Considerations , 1990 .

[89]  H. Holm,et al.  Ultrasonically guided 125iodine seed implantation with external radiation in management of localized prostatic carcinoma. , 1989, Urology.

[90]  D E Raeside,et al.  The accuracy of single-seed dose superposition for I-125 implants. , 1989, Medical physics.

[91]  D. Kuban,et al.  I–125 interstitial implantation for prostate cancer. What have we learned 10 years later? , 1989, Cancer.

[92]  C. Ling,et al.  Interface dosimetry for I-125 sources. , 1989, Medical physics.

[93]  R. Dale Radiobiological assessment of permanent implants using tumour repopulation factors in the linear-quadratic model. , 1989, The British journal of radiology.

[94]  R. Peschel,et al.  Iodine-125 implants versus external beam therapy for stages A2, B, and C prostate cancer. , 1988, International journal of radiation oncology, biology, physics.

[95]  David E. Goldberg,et al.  Genetic Algorithms in Search Optimization and Machine Learning , 1988 .

[96]  L L Anderson,et al.  A "natural" volume-dose histogram for brachytherapy. , 1986, Medical physics.

[97]  R. Peschel,et al.  Prostatic cancer therapy: comparison of external-beam radiation and I-125 seed implantation treatment of stages B and C neoplasms. , 1986, Radiology.

[98]  R G Dale,et al.  The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapy. , 1985, The British journal of radiology.

[99]  L. Anderson,et al.  The effects of permanent I-125 interstitial implantation on cortical bone. , 1985, International journal of radiation oncology, biology, physics.

[100]  W. Whitmore,et al.  Interstitial radiation: short-term palliation or curative therapy? , 1985, Urology.

[101]  E. Sternick,et al.  Tumor dose specification of I-125 seed implants. , 1985, Medical physics.

[102]  Encapsulated iodine-125 in radiation oncology. I. Study of the relative biological effectiveness (RBE) using low dose rate irradiation of mammalian cell cultures. , 1984, American journal of clinical oncology.

[103]  C. Ling,et al.  Physical dosimetry of 125I seeds of a new design for interstitial implant. , 1983, International journal of radiation oncology, biology, physics.

[104]  C. D. Gelatt,et al.  Optimization by Simulated Annealing , 1983, Science.

[105]  R G Dale,et al.  Some theoretical derivations relating to the tissue dosimetry of brachytherapy nuclides, with particular reference to iodine-125. , 1983, Medical physics.

[106]  F. Waterman,et al.  Absorbed dose determination for interstitial 125I boost therapy. , 1983, Medical physics.

[107]  H. Holm,et al.  Transperineal 125iodine seed implantation in prostatic cancer guided by transrectal ultrasonography. , 1983, The Journal of urology.

[108]  E. Hall,et al.  Studies with encapsulated 125I sources. II. Determination of the relative biological effectiveness using cultured mammalian cells. , 1981, International journal of radiation oncology, biology, physics.

[109]  Interstitial volume implants with I-125 seeds. , 1981, International journal of radiation oncology, biology, physics.

[110]  V. Krishnaswamy Dose tables for /sup 125/I seed implants , 1979 .

[111]  V. Krishnaswamy Dose tables for 125I seed implants. , 1979, Radiology.

[112]  L. Anderson,et al.  Dose inhomogeneity in interstitial implants using 125I seeds. , 1979, International journal of radiation oncology, biology, physics.

[113]  V. Krishnaswamy Dose distribution around an 125I seed source in tissue. , 1978, Radiology.

[114]  L L Anderson,et al.  Spacing nomograph for interstitial implants of 125I seeds. , 1976, Medical physics.

[115]  C G Orton,et al.  Time-dose factors (TDFs) in brachytherapy. , 1974, The British journal of radiology.

[116]  W. Whitmore,et al.  Radiation therapy and pelvic node dissection in the management of cancer of the prostate. , 1974, The American journal of roentgenology, radium therapy, and nuclear medicine.

[117]  W. Whitmore,et al.  Retropubic implantation to iodine 125 in the treatment of prostatic cancer. , 1972, The Journal of urology.

[118]  U. Henschke,et al.  Dimension averaging a simple method for dosimetry of interstitial implants. , 1968, Radiobiologia, radiotherapia.

[119]  O. Glasser Physical Foundations of Radiology , 1953 .